Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Lowered to $43.00 at The Goldman Sachs Group

Day One Biopharmaceuticals (NASDAQ:DAWN) had its price objective decreased by The Goldman Sachs Group from $48.00 to $43.00 in a research note released on Monday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock.

Several other brokerages also recently commented on DAWN. TD Cowen raised shares of Day One Biopharmaceuticals to a “strong-buy” rating in a research note on Monday, November 4th. Bank of America reduced their price target on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Needham & Company LLC restated a “buy” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Monday, January 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $35.71.

Day One Biopharmaceuticals Stock Performance

Shares of Day One Biopharmaceuticals stock opened at $11.87 on Monday. The firm has a fifty day moving average of $12.59 and a two-hundred day moving average of $13.61. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of -11.52 and a beta of -1.46. Day One Biopharmaceuticals has a 52 week low of $11.13 and a 52 week high of $18.07.

Insider Buying and Selling

In other news, insider Samuel C. Blackman sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $13.31, for a total transaction of $399,300.00. Following the transaction, the insider now directly owns 1,034,015 shares of the company’s stock, valued at approximately $13,762,739.65. This trade represents a 2.82 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 8.40% of the stock is currently owned by insiders.

Institutional Trading of Day One Biopharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the stock. FMR LLC boosted its stake in shares of Day One Biopharmaceuticals by 178.5% in the 3rd quarter. FMR LLC now owns 7,412,380 shares of the company’s stock valued at $103,254,000 after purchasing an additional 4,750,936 shares during the last quarter. Braidwell LP grew its holdings in Day One Biopharmaceuticals by 60.5% during the 3rd quarter. Braidwell LP now owns 4,873,853 shares of the company’s stock worth $67,893,000 after acquiring an additional 1,837,949 shares during the period. Franklin Resources Inc. grew its holdings in Day One Biopharmaceuticals by 2.3% during the 3rd quarter. Franklin Resources Inc. now owns 3,869,632 shares of the company’s stock worth $55,336,000 after acquiring an additional 87,262 shares during the period. Vestal Point Capital LP lifted its stake in shares of Day One Biopharmaceuticals by 100.0% in the 3rd quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company’s stock valued at $34,825,000 after purchasing an additional 1,250,000 shares during the period. Finally, Janus Henderson Group PLC boosted its position in shares of Day One Biopharmaceuticals by 18.4% during the 3rd quarter. Janus Henderson Group PLC now owns 2,177,197 shares of the company’s stock valued at $30,307,000 after purchasing an additional 337,928 shares in the last quarter. 87.95% of the stock is currently owned by institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.